Harvard Bioscience Inc. has announced a CEO succession plan, with current Board member John Duke set to become President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green is retiring after over 8 years as Chairman and 6 years as President & CEO. Additionally, Rob Gagnon and Seth Benson have been appointed as new independent Board members. The company anticipates Q2 2025 revenue of $20.4 million and maintains its previously announced gross margin guidance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495983-en) on July 17, 2025, and is solely responsible for the information contained therein.